Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
A phase 1/2 trial of Opevesostat in prostate cancer, run by Orion Corporation, Orion Pharma, active and no longer recruiting.
Overview
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT03436485 by Orion Corporation, Orion Pharma, with 204 participants enrolled, started 2018-03-19 and due to reach its primary completion in 2026-10-31. Interventions recorded: ODM-208, Midazolam. Conditions listed: Prostate Cancer Metastatic. No results are recorded here; the registry entry is the source.
Setting
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
Phase
Phase 1/2
Sponsor
Orion Corporation, Orion Pharma
Registry
Enrolled
204
Similar pages
not linked directly; found by shared links- TrialStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Shares Opevesostat, Prostate cancer.
- TrialA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Shares Opevesostat, Prostate cancer.
- TrialA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Shares Opevesostat, Prostate cancer.
- TrialSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Shares Opevesostat, Prostate cancer.